HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jan. 25, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that NicAlert(TM), the Company’s tobacco exposure test, has achieved certification with the CE Mark. The CE Mark indicates that the product complies with EU safety, environmental, and quality standards and makes the product eligible for sale in the European Union. NicAlert(TM) previously received clearance from the U.S. Food and Drug Administration for determining smoking status for medical uses in the U.S. Nymox has satisfactorily completed the testing and registration required to obtain CE Marking for the NicAlert(TM) test.
